Parkinson’s disease is the second most common neurodegenerative disorder and the most common movement disorder. It is characterized by progressive loss of muscle control, which leads to trembling of the limbs and head while at rest, stiffness, slowness, and impaired balance. As symptoms worsen, it may become difficult to walk, talk, and complete simple tasks.
The progression of Parkinson’s disease and the degree of impairment vary from individual to individual. Many people with Parkinson’s disease live long productive lives, whereas others become disabled much more quickly. Premature death is usually due to complications such as falling-related injuries or pneumonia.
In the United States, about 1 million people are affected by Parkinson’s disease and worldwide about 5 million. Most individuals who develop Parkinson’s disease are 60 years of age or older. Parkinson’s disease occurs in approximately 1% of individuals aged 60 years and in about 4% of those aged 80 years. Since overall life expectancy is rising, the number of individuals with Parkinson’s disease will increase in the future. Adult-onset Parkinson’s disease is most common, but early-onset Parkinson’s disease (onset between 21-40 years), and juvenile-onset Parkinson’s disease (onset before age 21) also exist.
USACIG, maker of the “e-cig” announced they have signed an exclusive agreement with Hop-on to submit it’s electronic cigarette technology to the FDA for clinical studies for the prevention and treatment of Parkinson’s disease.
Recent studies by the Parkinson’s Institute and Clinical Center lead by Maryka Quik, Ph D have indicated intermittent nicotine treatment can reduce medication induced dyskinesias by as much as 50%. USACIG is hoping their electronic cigarette might be the perfect way to deliver nicotine to Parkinson’s patients.
Peter Michaels, CEO of Hop-on, the company one usually associates with multi media services, the first disposable cell phone and the licencing of technology like CDMA, GSM and WIFI, says they are excited to be the exclusive agent for FDA submission.
“Studies on nicotine through e cigarette use have proven to delay the onset of Parkinson’s disease. Nicotine in its natural state removed from cigarettes is safe and non-toxic. USACIG nicotine water technology delivers pure organic and non-toxic nicotine without harmful chemicals. While nicotine has had an image problem due to its association with smoking, there is much excitement about nicotine’s potential to prevent and help with a number of medical issues. We are very excited about being USACIG’s exclusive agent for FDA submission. USACIG will be working on the funding for clinical studies.”
USACIG, which manufactures it’s cartridges in the US while the electronics are made in China, has been planning for something like this and has some US doctors on their board “to supervise any medical related issues or opportunities.” USACIG is now is in the process of securing funding to start up the clinical trials while Hop-on handles the FDA submission.
Will the Electric Cigarette prove to be a valuable treatment for Parkinson’s disease?